Sadly I don't expect much support since as stated in the article, "There is also the likelihood that more refined testing will shrink the patient population that drug companies can target with new analgesic drugs. Instead of getting an approval for all of post-herpetic neuralgia, for example, they'd get one just for post-herpetic neuralgia with allodynia."

Regardless, it is very interesting and good to know.